Jim Cramer’s Lightning Rounds: 9 Stocks in Focus

2. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Holders: 50

A caller highlighted that while Sarepta Therapeutics, Inc. (NASDAQ:SRPT) exceeded earnings expectations and reiterated its guidance for this year, they found the price a little confusing. Here’s what Cramer said in response:

“You’re totally right. I, the RNA-based therapeutic companies are not doing well. I wonder if this isn’t like a reverse halo effect because of Moderna. I didn’t quite understand, I agree with you. It, it is troubling. I don’t want to be there.”

Sarepta Therapeutics (NASDAQ:SRPT) develops RNA-targeted and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy and ongoing research into new genetic therapies. Previously, Cramer discussed the company in July 2024 and said:

“I think Sarepta is a speculative situation where they have great science. I am never going to bet against a biotech company with great science, therefore I bless owning the stock. It’s too risky for me, but it’s ok if you want to be there.”